Although Tirzepatide/Mounjaro® is the only currently FDA-approved multi-agonist, several additional incretin-based dual or triple agonists are in clinical trials for T2DM and obesity, including the triple agonist (Retatrutide) used in this study [96]. Here, GCG is linked to type 2 diabetes mellitus.